rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
|
25311215 |
2014 |
rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.
|
24627688 |
2014 |
rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design.
|
24846033 |
2014 |
rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
|
23562183 |
2013 |
rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group.
|
23667368 |
2013 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
|
23833300 |
2013 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
|
22649091 |
2012 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
|
21483012 |
2011 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
|
19238210 |
2009 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Genetic predictors of MEK dependence in non-small cell lung cancer.
|
19010912 |
2008 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Missense mutations of the BRAF gene in human lung adenocarcinoma.
|
12460919 |
2002 |
rs121913351
|
|
Carcinoma of lung
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Missense mutations of the BRAF gene in human lung adenocarcinoma.
|
12460919 |
2002 |
rs113488022
|
|
Carcinoma of lung
|
|
0.750 |
GeneticVariation
|
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
rs113488022
|
|
Carcinoma of lung
|
|
0.750 |
GeneticVariation
|
BEFREE |
Success of this design of clinical trials and practice was first demonstrated in EGFR inhibitor trials in lung cancer and has since been incorporated into subsequent targeted therapy trials including ALK-, ROS1-, and BRAF V600E-targeted therapies.
|
28786099 |
2017 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
|
23833300 |
2013 |
rs113488022
|
|
Carcinoma of lung
|
|
0.750 |
GeneticVariation
|
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
|
23524406 |
2013 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
|
22649091 |
2012 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
|
22743296 |
2012 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
|
22773810 |
2012 |
rs113488022
|
|
Carcinoma of lung
|
|
0.750 |
GeneticVariation
|
BEFREE |
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
|
21483012 |
2011 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
|
21483012 |
2011 |